Protective Effects of Hyperpolarizing Cardioplegia with Pinacidil on Myocardium in Rats

Whether the ATP sensitive potassium channel opener pinacidil can provide myocardial protective effects in prolonged isolated global ischemic rat heart was investigated. On modified isolated rat working heart model, 40 hearts were divided into four groups randomly: Hyperpolarized arrest H K solution containing pinacidil (50 μmol/L) (P1 and P2) and depolarized arrest St. Thomas' solution (S1 and S2) subjected to 15 ℃ hypothermia, 60 min (P1 and S1) or 120 min (P1 and S2) of ischemia and 30 min reperfusion. The experimental indices included cardioplegic efficiency, cardiac function, coronary blood flow, myocardial enzyme release, myocardial water and ATP content. Hyperpolarized arrest provided significantly better recovery of cardiac function than depolarized arrest. Postischemic coronary flow and myocardial ATP content were higher. The arrest time of electro mechanical activities were longer than depolarized arrest. There were no differences among the groups in myocardial water contents. The hyperpolarized arrest solution containing pinacidil can provide a marked myocardial protective effect during prolonged hypothermic myocardial ischemia.

Tepid antegrade intermittent blood cardioplegia as an alternative for intermittent crossclamping with Lidoflazine

Background: Blood cardioplegia is a technique with many variations in its use. Intermittent cross clamping with Lidoflazine has proven to deliver good cardioprotection in our center. Question: Is tepid (32°C) antegrade intermittent blood cardioplegia an efficient, safe and easy-to-use alternative to intermittent cross-clamping with Lidoflazine in elective isolated CABG in low-risk patients? Primary outcomes are heart enzymes (cTnI, CK-MB). Secondary outcomes are operation times, length of hospital stay, major complications and in-hospital mortality. Methods: From January 2012 until November 2012, 40 patients with LVEF ≥50%, EuroSCORE

Is there a rationale for short cardioplegia re-dosing intervals?

While cardioplegia has been used on millions of patients during the last decades, the debate over the best technique is still going on. Cardioplegia is not only meant to provide a non-contracting heart and a field without blood, thus avoiding the risk of gas emboli, but also used for myocardial protection. Its electromechanical effect is easily confirmed through direct vision of the heart and continuous electrocardiogram monitoring, but there is no consensus on the best way to assess the quality of myocardial protection. The optimal approach is thus far from clear and the considerable amount of literature on the subject fails to provide a definite answer. Cardioplegia composition(crystalloid vs blood, with or without various substrate enhancement), temperature and site(s) of injection have been extensively researched. While less frequently studied, re-dosing interval is also an important factor. A common and intuitive idea is that shorter redosing intervals lead to improved myocardial protection. A vast majority of surgeons use re-dosing intervals of 20-30 min, or even less, during coronary artery bypass graft and multidose cardioplegia has been the "gold standard" for decades. However, one-shot cardioplegia is becoming more commonly used and is likely to be a valuable alternative. Some surgeons prefer the comfort of single-shot cardioplegia while others feel more confident with shorter re-dosing intervals. There is no guarantee that a single strategy can be safely applied to all patients, irrespective of their age, comorbidities or cardiopathy. The goal of this review is to discuss the rationale for short re-dosing intervals.

Clinical study of applying fructose-1,6-diphosphate and captopril to enhance the protective effects of cardioplegia solution on ischemic myocardium

In the present experiment,fructose-1,6-diphosphate（FDP）and captopril（Cap）wereadded to the cold potassium cardioplegia solution and the levels of malondialdehyde（MDA）,cre-atine phosphokinase MB（CPK-MB）,thromboxane B（TXB2）and 6-keto-PGF1α in plasma weremeasured during open-heart surgery.Quantitative study of myocardial ultrastructure and obser-vation of cardiac resuscitation were also undertaken.The findings suggested that FDP,especiallywhen combined with Cap could significantly strengthen the protective effects of cold potassiumcardioplegia solution on ischemic myocardium.

Effect of Amino Acid Cardioplegia on Myocardial Metabolism and Function of Ischemic Canine Heart

To evaluate the effect of amino acid cardioplegia on myocardial metabolism and function of ischemic canine heart, canine cardiopulmonary bypass (CPB) model was established and the dog heart was subjected to a 120 min ischemic arrest. Animals were divided into 3 groups, group 1:warm blood cardioplegia induction and terminal perfusion plus 4 C ST. Thomas hospital solution (STS)during ischemia;group 2: warm blood cardioplegia enriched with amino acid (L-asparte and L-glutamate 13 mmol/L each) and STS without amino acid (A.G.) and group 3:both warm blood cardioplegic solution and STS enriched with A. G..The result demonstrated that the cardiac function of animals in group 2 and 3 had a significantly better recovery after ischemic-re-perfusion. By the end of ischemia the content of myocardial ATP in group 3 was distinctly higher than that in group 1(P<0. 05), with the release of cardiac enzyme being the least. Myocardial ultra-structure almost remained intact before and after ischemia. Our experiment suggests that the cardioplegia arrest with warm blood and cold crystalloid solution enriched with amino acids could diminish the ischemia-re-perfusion injuries of the heart and enhance the effect of myocardial protection.

The release of cardiac specific serum enzymes as an index for the evaluation of myocardial protection with cold blood and crystalloid cardioplegia

Myocardial protection during open heart surgery was studied in 52 patients with complex congenital heart disease. Twenty-six patients received b1ood cardioplegia (BCP) and 26 crystalloid cardioplegia (CCP). Release of serum enzymes (creatine kinase, CK; hybrid muscle-brain CK isoenzyme, CK-MB; aspartate aminotransferase, ASTF and 1actic dehydrogenase, LDH) was determined pre-and post-operatively. DUring the first 72 h post-operation, release of CK, CK-MB, AST and LDH in the 2 groups was different, In case of tetralogy of Fallot (TOF) the CK-MB released in l3CP and CCP 12 h after operation were 51. 29±9. 42 and 85. 77±22. 39 U/L respectively (P<0. 05). In the CCP group of TOF, CK-MB level increased significantly even at 72 h after operation (30. 91±14. 32 U/L vs the pre-operative value of 14. 57±7. 51 U/L). The results show a better myocardial preservation in the BCP group as compared with the CCP group. BCP can maintain metabolic homeostasis of the myocardium, reduce myocardial injury and increase the content of myocardial high energy phosphate during ischemia. Tolerance to ischemia is poor in patients with complex congenital heart disease. Therefore, preservation of high energy phosphates is necessary for severe-grade patients and BCP is superior to crysta1loid cardioplegia in this regard. It is concluded that CCP results in a higher release of CK-MB as compared with BCP group. BCP is superior to CCP for myocardial protection in patients with complex congenital heart disease.

Effect of Cardioplegia for Myocardial Protection in Pediatric Cardiac Surgery:A Network Meta-Analysis

Cardioplegia has been widely used to reduce myocardial injury during pediatric cardiac surgery;however,which cardioplegia solution has the best protective effect has not been established.Thus,we compared the myocardial protective effects of different cardioplegia solutions used in pediatric cardiac surgery.Seven databases were searched to identify the relevant randomized controlled trials.A network meta-analysis with a Bayesian framework was conducted.The outcomes included the following biochemical and clinical outcomes:serum concentrations of the creatine kinase-myocardial band at 6 h postoperatively;cardiac troponin I(cTnI)at 4,12,and 24 h postoperatively;spontaneous beating after declamping;postoperative arrhythmias;inotropic support percentage and duration;mechanical ventilation hours;intensive care unit stay in days;hospital stay in days;and mortality.The group treated with cold crystalloid cardioplegia(cCCP)was chosen as the control group.The 22 studies involved 1529 patients.Six types of cardioplegia solutions were described in these studies,including cold blood cardioplegia,cCCP,del Nido,histidine-tryptophan-ketoglutarate(HTK),terminal warm blood cardioplegia,and warm blood cardioplegia(wBCP).The serum concentrations of the 24-h cTnI with wBCP(MD=−2.52,95%CI:−4.74 to−0.27)was significantly lower than cCCP.The serum concentrations of the 24-h cTnI with HTK(MD=4.91,95%CI:2.84–7.24)was significantly higher than cCCP.There was no significant difference in other biochemical and clinical outcomes when compared to cCCP.In conclusion,wBCP may have a superior myocardial protective effect with lower 24-h cTnI levels postoperatively and similar clinical outcomes after pediatric cardiac surgery.

改良Del Nido与国产HTK停搏液在成人心脏瓣膜置换术中的应用效果

目的:分析改良Del Nido与国产HTK停搏液在成人心脏瓣膜置换术中的应用效果。方法:回顾性分析2022年1月—2023年7月钦州市第一人民医院收治的60例心脏瓣膜置换术患者资料。根据停搏液使用情况将其分为DN组(30例)和HTK组(30例)。HTK组使用国产HTK停搏液,DN组使用改良Del Nido停搏液。比较两组围手术期指标,术后24 h、48 h相关指标及肾功能。结果:DN组灌注次数多于HTK组,术后机械通气时间长于HTK组,主动脉阻断时间短于HTK组,自动复跳率高于HTK组,差异有统计意义(P<0.05)。两组术后24 h、48 h心肌肌钙蛋白(cTnI)、肌酸激酶同工酶(CK-MB)水平比较,差异无统计意义(P>0.05)。两组术后24 h、48 h血尿素氮(BUN)、血肌酐(Scr)水平比较,差异无统计意义(P>0.05)。结论:与国产HTK停搏液对比,改良Del Nido停搏液应用于成人心脏瓣膜置换术中能缩短主动脉阻断时间,提高自动复跳率,灌注次数较多,术后机械通气时间较长,但两者均具有良好的心肌保护作用。

Ischemic preconditioning in immature hearts: mechanism and compatibility with cardioplegia

To investigate (1) whether ischemic preconditioning (IPC) could protect immature rabbit hearts against ischemia reperfusion injury and (2) the role of K ATP channel in the mechanism of myocardial protection Since cardioplegia is a t raditional and effective cardioprotective measure in clinic, our study is also d esigned to probe the compatibility between IPC and cardioplegia Methods New Zealand rabbits aged 14-21 days weighing 220-280 g were used The animals w ere anesthetized and heparinized The chest was opened and the heart was quickl y removed for connection of the aorta via Langendorff's method within 30 s after excision All hearts were perfused with Krebs Henseleit buffer balanced with gas mixture (O 2∶CO 2=95%∶5%) at 60 cm H 2O (perfusion pressure) IPC cons isted of 5 min global ischemia plus 10 min reperfusion Glibenclamide was used as the K ATP channel blocker at a concentration of 10 μmol/L before IPC Cardiac arrest was induced with 4℃ St Thomas cardioplegic solution, at which point the heart was made globally ischemic by withholding perfusion for 45 min f ollowed by 40 min reperfusion Thirty immature rabbit hearts were randomly divi ded into four groups: CON (n=9) was subjected to ischemia reperfusion only; IPC ( n=9) underwent IPC and ischemia reperfusion; Gli (n=6) was given glibenclamide and ischemia reperfusion; and Gli+IPC (n=6) underwent glibenclamide, IPC and is chemia reperfusion Coronary flow (CF), HR, left ventricle developed pressure (LVDP), and ±dp/dt max were monitored at equilibration (baseline value) an d 5, 1 0, 20, 30 and 40 min after reperfusion The values resulting from reperfusion w ere expressed as a percentage of their baseline values Arrhythmia quantificati on, myocardial enzyme in the coronary effluent and myocardial energy metaboli sm were also determined Results The recovery of CF, HR, LVDP and ±dp/dt max in preconditioned hearts was b est am ong the four groups The incidence of arrhythmia was low and less CK MB leaked out in the IPC group Myocardial ATP content was better preserved by IPC Pre treatment with glibenclamide completely abolished the myocardial protection prov ided by IPC, but did not affect ischemia reperfusion injury Conclusions While applying cardioplegia, IPC provides significant cardioprotective effects Activation of K ATP channels is involved in the mechanism of IPC produced cardioprotection

两种心脏停搏液在体外循环下单纯心脏瓣膜置换术中的心肌保护效果

目的:比较两种心脏停搏液在体外循环下单纯心脏瓣膜置换术中的心肌保护效果。方法:将2019年5月至2022年7月四川省人民医院收治的108例单纯心脏瓣膜置换术患者分为两组,A组53例,使用组氨酸-色氨酸-酮戊二酸(HTK)液;B组55例,使用含血St.Thomas液。比较两组体外循环术中情况如体外循环时间、主动脉阻断时间、灌注次数、心脏复跳时间、心脏自动复跳率,主动脉阻断前以及术后2、12、24、48、72 h时血清肌钙蛋白Ⅰ(cTnⅠ)、肌酸激酶同工酶(CK-MB)、脑钠肽(BNP)、心型脂肪酸结合蛋白(HFABP)、丙二醛(MDA)、超氧化物歧化酶(SOD)水平,转流过程中血K^(+)、Na^(+)浓度,手术前后心排量与心指数,术后24 h多巴胺的用量及并发症等。结果:A、B组体外循环时间、主动脉阻断时间差异无统计学意义(P>0.05),A组灌注次数少于B组,心脏复跳时间短于B组,心脏自动复跳率高于B组(P<0.05);A组术后2、12、24、48 h时血清cTnⅠ、CK-MB、BNP、HFABP、MDA水平低于B组,SOD水平高于B组(P<0.05);A组转流中、转流后即刻血K^(+)、Na^(+)水平低于B组(P<0.05);A组术后12、24 h心排量与心指数高于B组(P<0.05);A组术后24 h多巴胺用量少于B组(P<0.05)。两组术后并发症发生率差异无统计学意义(13.2%vs 21.8%,P=0.240)。结论:相较于含血St.Thomas液,HTK液应用于体外循环下单纯心脏瓣膜置换术,心肌保护效果更佳。

两种进口停搏液在心脏瓣膜置换术中的临床效果比较

目的本文旨在对del Nido心肌停搏液(DN)与组氨酸-色氨酸-酮戊二酸停搏液(HTK)在心脏瓣膜置换术中的临床效果进行回顾性分析,以期为其临床应用提供参考。方法回顾性分析2018年1月1日至2023年9月10日期间496例在本院心血管外科就诊的患者资料。按照排除标准剔除部分资料,并使用SPSS 22.0统计软件包对两组患者的部分特征进行倾向性评分匹配,最终纳入102例患者,其中DN组51例,HTK组51例。记录两组患者术中特征,并对比术后两组患者不同时间血清肌酸激酶同工酶(CKMB)、心肌肌钙蛋白I(cTnI)、血气分析和并发症情况。取入ICU时间点的心肌损伤标志物与主动脉阻闭时间进行相关性分析。最后将主动脉阻闭时间分为<90 min与90~120 min两组进行亚组分析。结果两组患者基本特征在倾向性匹配前与匹配后均无统计学意义。术中DN组与HTK组的停搏液+总量、K浓度、心肺转流时间与主动脉夹闭时间在倾向性匹配前后差异均具有统计学意义(P<0.05)。DN组(R=0.878,R=0.758,P<0.001)与HTK组(R=0.951,R=0.925,P<0.001)的主动脉夹闭时间与CKMB、cTnI具有一定的相关性。亚组分析显示在90~120 min内DN组与HTK组的CKMB、cTnI值差异具有统计学意义(P<0.05)。结论两种停搏液均具有较高的安全性。在主动脉阻断时间<90 min时的两组心肌保护效果无明显差异,90~120 min时DN可能具有更好的心肌保护效果。

del Nido和HTK停搏液在成人左心室肥厚患者心脏手术中心肌保护效果的比较

目的:探讨del Nido停搏液和组氨酸⁃色氨酸⁃酮戊二酸(histidine⁃tryptophan⁃ketoglutarate,HTK)停搏液在左心室肥厚(left ventricular hypertrophy,LVH)患者行心内直视手术中的临床应用效果。方法:回顾性收集2021年1月—2022年12月在南京医科大学第一附属医院心脏大血管外科进行心脏体外循环手术的LVH患者75例,根据术中使用停搏液类型分为del Nido组(D组,39例)和HTK组(H组,36例)。比较两组患者一般资料、手术麻醉与体外循环资料、术后临床资料及围术期心肌标志物改变等。结果:升主动脉开放后,D组室颤发生率低于H组(P<0.01)。发生室颤患者中,D组的室颤持续时间、除颤次数和除颤能量均低于H组(P<0.05)。D组复跳时间长于H组(P<0.05),D组临时起搏器使用率高于H组(P<0.05)。体外循环结束后15 min,D组血管活性药评分(vasoactive⁃inotropic score,VIS)高于H组(P<0.001);而手术结束前15 min以及术后6 h两组VIS评分比较,差异无统计学意义(P>0.05)。在心肌标志物方面,仅发现术后24 h,H组肌酸激酶同工酶(creatine kinase⁃MB,CK⁃MB)和肌钙蛋白T(cardiac troponin T,cTnT)高于D组(P<0.05);两组术后48 h心肌标志物比较,差异无统计学意义(P>0.05)。结论:del Nido停搏液和HTK停搏液均可安全用于LVH患者术中心肌保护,但使用HTK停搏液,主动脉开放后室颤发生率更高,术后24 h CK⁃MB及cTnT高于del Nido停搏液;而使用del Nido停搏液,心脏复跳时间更长,临时起搏器使用率更高,且停机后15 min时的血管活性药使用量高于HTK停搏液。

MORPHOMETRIC EVALUATION ON MYOCARDIAL PROTECTION OF COLD CRYSTALLOID VERSUS WARM BLOOD CARDIOPLEGIA

Twenty patients undergoing open-heart valve replacement were divided randomly into two groups in this study; intermittent perfusion of cold crystalloid (St. Thomas Hospital solution) with hypothermic cardiopulmonary bypass (CPB) (hypothermic group) and continuous administration of warm blood cardioplegia with normothermic CPB (normothermic group) respectively. Tissue samples were taken from the right atrium before weaning from CPB and from the right appendage 30 minutes after removal of the cross-clamp. The results of pathological study in these two groups were as follows: the structural alterations were most severe during the ischemic period in the hypothermic group. Damages of the myocardial

胸腔镜辅助右腋下小切口心脏手术中使用改良del Nido液临床经验总结

目的总结胸腔镜辅助右腋下小切口心脏手术中使用改良del Nido液行心肌保护的临床效果。方法回顾性分析本院自2018年开展胸腔镜辅助右腋下小切口心脏手术以来,采用4份血比1份del Nido液混合组成改良del Nido液,以每隔60 min复灌一次的方法实施心肌保护措施的患者临床资料。包括患者术前一般特征、术中资料、术后心肌损伤标志物与术后转归等。结果5年期间体外循环中采用改良del Nido液使心脏停跳下微创手术908例。围术期主要指标:①心脏自动复跳率为93.28%。②所有患者术后24 h内心肌肌钙蛋白I(cTnI)较术前均有明显增高(P<0.05)。主动脉阻断时间在90 min内,单次灌注时间≤60 min与61~90 min组相比较cTnI无显著性差异(P=0.116);主动脉阻断时间超过90 min,cTnI随着灌注间隔时间延长而增高,灌注间隔时间61~90 min组与>90 min组比较无显著性差异,但均较≤60 min组显著增高(P=0.026,P=0.010)。③微创心脏手术总体预后较佳,术后30 d内死亡率仅1.87%。结论在胸腔镜辅助右腋下小切口心脏手术中使用改良del Nido液单次灌注可使心脏长时间停搏;每隔60 min间断灌注心肌及单次灌注不超过90 min是安全有效的。

康斯特保护液与含血停搏液在肥厚型梗阻性心肌病术中的心肌保护效果

目的:评价康斯特心肌保护液(histidine-tryptophan-ketoglutarate solution,HTK)与含血停搏液在肥厚型梗阻性心肌病(hypertrophic obstructive cardiomyopathy,HOCM)外科手术中的心肌保护效果。方法:回顾性分析首都医科大学附属北京安贞医院,2015年1月至2021年12月间,心脏外科HOCM行外科手术治疗患者临床资料,按照术中使用停搏液不同,分为HTK液组(HG,n=200)和含血停跳液组(BG,n=118),比较两组患者手术情况和术后恢复情况。结果:5例(1.6%)患者住院死亡,其中4例(2.0%)为HG组,1例(0.9%)为BG组,差异无统计学意义(P>0.05)。HG组患者术中平均阻断升主动脉时间[81(76,103)vs.76.6(49,88)min]和体外循环转机时间[118.5(92,152)vs.112.5(78,134)min]均稍长,但差异无统计学意义(P>0.05);HG组患者自动复跳率较低(29.0%vs.56.8%,P<0.01)。HG组患者术后平均肾上腺素使用时间较BG组短[15.7(0,18)vs.27.6(0,28)h,P=0.025];与BG组患者相比较,HG组患者术后ICU停留时间较短[30.6(16.0,29.0)vs.40.9(18.0,38.5)h,P=0.015]。结论:HTK液与含血停跳液均可安全用于HOCM患者外科手术,尽管HTK液组患者开放升主动脉后自动复跳率较低,但有较好心肌保护效果,能有效促进患者术后恢复。

HTK液与del Nido液在心脏瓣膜手术中心肌保护效果对比分析

目的回顾性分析比较在心脏瓣膜手术中HTK停搏液与del Nido停搏液的心肌保护效果。方法收集选取2019年1月至2021年12月在阜外华中心血管病医院行体外循环(CPB)下心脏直视手术的153例成人心脏瓣膜患者纳入研究。依据使用心脏停搏液不同而分为两组,HTK停搏液组(71例)和del Nido停搏液(冷D组,82例)。采集血液中心肌损伤标志物数据及愈后情况作临床比较。结果两组在CPB时间、升主动脉阻断时间、术后机械通气时间、ICU停留时间、术后出院时间、电击复跳率、术后并发症的发生率及病死率等方面均无统计学差异(P>0.05);两组在术后24h血液指标中超敏肌钙蛋白(P=0.08)、肌酸激酶(P=0.68)、心肌肌酸激酶同工酶(P=0.06)、N端-BNP(P=0.05)无统计学差异(P>0.05)。在停搏液灌注用量方面冷D组较少(P=0.001),HTK组所需灌注次数更少(P<0.001)。出院后1月门诊复查,两组患者左心室射血分数值、左心室收缩末内径,左心室舒张末内径无显著性差异(P>0.05)。结论在心脏瓣膜手术中,应用HTK停搏液及delNido停搏液都具有良好的心肌保护效果。

二尖瓣置换术Del Nido停搏液与St.Thomas停搏液心肌保护比较

目的比较Del Nido停搏液与St.Thomas停搏液在成人二尖瓣置换术中的心肌保护效果。方法分析2020年4月至2021年6月新乡医学院第一附属医院心血管外科收治的60例行体外循环下单纯二尖瓣置换术患者的临床资料,根据心脏停搏液的不同分为Del Nido组和St.Thomas组,每组30例。比较两组术中体外循环时间、主动脉阻断时间、心脏停搏液灌注次数以及术后心肌肌钙蛋白I(cTnI)和肌酸磷酸激酶同工酶(CK-MB)水平、多巴胺使用时间、重症监护病房住院时间、机械通气时间和心律失常发生情况。结果Del Nido组术中停搏液灌注次数、主动脉阻断时间均明显少于St.Thomas组[1.0(1.0,1.0)次比3.0(2.0,3.0)次、(88.3±9.5)min比(111.0±9.8)min](P<0.01)。但两组患者术中体外循环时间、机械通气时间以及术后重症监护病房住院时间、多巴胺使用时间、cTnI水平、CK-MB水平比较差异均无统计学意义(P>0.05)。Del Nido组术后心律失常发生率低于St.Thomas.Thomas组[3.3%(1/30)比23.3%(7/30)](P<0.05)。结论在成人二尖瓣置换术中,与St.Thomas停搏液相比,Del Nido停搏液灌注次数更少、主动脉阻断时间更短、术后心律失常发生率更低。

心脏停搏液的临床应用进展

良好的心肌保护是影响心脏手术成功的关键因素之一,而心脏停搏液是心肌保护的基石,在心肌保护中扮演着重要的角色。本文将对心脏停搏液的各要素比如停搏液设计、停搏液类型、灌注方式、停搏液温度等进行综述。

终末温血逆灌结合del Nido心脏停搏液在成人心脏外科手术中的心肌保护作用

目的研究终末温血逆灌结合del Nido心脏停搏液在成人心脏外科手术中的心肌保护作用。方法回顾性分析2017年12月至2020年1月间161名于复旦大学附属中山医院心脏外科行心脏手术的患者,所有患者均使用del Nido心脏停搏液进行心脏停跳,根据患者在升主动脉开放前是否接受终末温血逆灌分为温血逆灌组(62人)和非温血逆灌组(99人)。收集并分析两组患者一般情况,术前、术中及术后相关临床资料。结果经过倾向性匹配分析,温血逆灌组及非温血逆灌组各50人,两组患者在术前、术中临床资料均无显著性差异。术后肌钙蛋白T值、脑钠肽值,心肺转流结束时正性肌力药物使用情况,住院死亡率,ICU滞留时间等无显著性差异。结论在成人心脏外科手术中,终末温血逆灌不能提高del Nido心脏停搏液的心肌保护作用。

HTK液与高钾停搏液在成人心脏手术中心肌保护效果的荟萃分析

目的通过比较成人心脏手术中HTK液和高钾停搏液的心肌保护效果,探讨最佳的心肌保护方法。方法检索主要中外生物医学数据库(2005.10~2016.11)文献,收集HTK液与高钾停搏液心肌保护比较的随机对照研究,以Cochrane系统工具评价纳入研究的偏倚风险,对提取的结局指标进行Meta分析。结果最终纳入研究13篇,共含1 047个病例,其中HTK组(实验组)502例,高钾组(对照组)545例;各组研究经检验无统计学异质性,采用固定模型合并。4项研究比较了两组CK-MB峰值,两组的CK-MB峰值无统计学差异(SMD=0.20,95%CI:-0.06~0.46,P=0.21);4项研究比较了两组30d死亡率,两组的30d死亡率无统计学差异(OR=0.53,95%CI:0.22~1.26,P=0.66);6项研究比较了两组自动复跳率,两组的自动复跳率无统计学差异(OR=1.42,95%CI:0.98~2.07,P=0.12)。结论成人心脏手术中,HTK液与高钾停搏液心肌保护效果无差异。